Asher Chanan‐Khan

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Donna M. Weber, Christine Chen, Rubén Niesvizky et al. · New England Journal of Medicine · 2007 · 1.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees et al. · Blood · 2007 · 768 citations · Full text

Medicine, Oncology, Pharmacology +13

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Shaji Kumar, J H Lee, Juan José Lahuerta et al. · Leukemia · 2011 · 721 citations

Medicine, Hematology, Pharmacotherapy +15

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 655 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11